ID   KPCD3_HUMAN             Reviewed;         890 AA.
AC   O94806; D6W587; Q53TR7; Q8NEL8;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   15-MAR-2017, entry version 165.
DE   RecName: Full=Serine/threonine-protein kinase D3;
DE            EC=2.7.11.13;
DE   AltName: Full=Protein kinase C nu type;
DE   AltName: Full=Protein kinase EPK2;
DE   AltName: Full=nPKC-nu;
GN   Name=PRKD3; Synonyms=EPK2, PRKCN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=10231560; DOI=10.1016/S0167-4889(99)00040-3;
RA   Hayashi A., Seki N., Hattori A., Kozuma S., Saito T.;
RT   "PKCnu, a new member of the protein kinase C family, composes a fourth
RT   subfamily with PKCmu.";
RL   Biochim. Biophys. Acta 1450:99-106(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   THR-128 AND ARG-546.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   ENZYME REGULATION, SUBCELLULAR LOCATION, PHORBOL-ESTER BINDING, AND
RP   MUTAGENESIS OF THR-156; TYR-158; PRO-165; THR-166; TYR-170; PRO-282
RP   AND LYS-293.
RX   PubMed=18076381; DOI=10.1042/BJ20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual
RT   C1 domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; SER-27; SER-37;
RP   SER-41; SER-213; SER-216; SER-364 AND THR-535, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41; SER-44 AND
RP   SER-364, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41; SER-213;
RP   SER-216; SER-364 AND THR-535, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41 AND SER-44,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-44 AND SER-364,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   STRUCTURE BY NMR OF 414-532.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PH domain of protein kinase C, nu type from
RT   human.";
RL   Submitted (JAN-2007) to the PDB data bank.
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-716.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Converts transient diacylglycerol (DAG) signals into
CC       prolonged physiological effects, downstream of PKC. Involved in
CC       resistance to oxidative stress (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domains 1 and 2 bind both DAG and phorbol ester
CC       with high affinity and mediate translocation to the cell membrane.
CC       Autophosphorylation of Ser-735 and phosphorylation of Ser-731 by
CC       PKC relieves auto-inhibition by the PH domain.
CC       {ECO:0000269|PubMed:18076381}.
CC   -!- INTERACTION:
CC       P63027:VAMP2; NbExp=7; IntAct=EBI-1255366, EBI-520113;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18076381}.
CC       Membrane {ECO:0000269|PubMed:18076381}. Note=Translocation to the
CC       cell membrane is required for kinase activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O94806-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O94806-2; Sequence=VSP_029405, VSP_029406;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PKD subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB015982; BAA36514.1; -; mRNA.
DR   EMBL; AC007390; AAY14817.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00398.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00399.1; -; Genomic_DNA.
DR   EMBL; BC030706; AAH30706.1; -; mRNA.
DR   CCDS; CCDS1789.1; -. [O94806-1]
DR   RefSeq; NP_005804.1; NM_005813.4. [O94806-1]
DR   RefSeq; XP_005264294.1; XM_005264237.3. [O94806-1]
DR   UniGene; Hs.660757; -.
DR   UniGene; Hs.716034; -.
DR   PDB; 2D9Z; NMR; -; A=417-532.
DR   PDBsum; 2D9Z; -.
DR   ProteinModelPortal; O94806; -.
DR   SMR; O94806; -.
DR   BioGrid; 117199; 9.
DR   IntAct; O94806; 13.
DR   MINT; MINT-5003932; -.
DR   STRING; 9606.ENSP00000234179; -.
DR   BindingDB; O94806; -.
DR   ChEMBL; CHEMBL2595; -.
DR   GuidetoPHARMACOLOGY; 2174; -.
DR   iPTMnet; O94806; -.
DR   PhosphoSitePlus; O94806; -.
DR   BioMuta; PRKD3; -.
DR   EPD; O94806; -.
DR   MaxQB; O94806; -.
DR   PaxDb; O94806; -.
DR   PeptideAtlas; O94806; -.
DR   PRIDE; O94806; -.
DR   DNASU; 23683; -.
DR   Ensembl; ENST00000234179; ENSP00000234179; ENSG00000115825. [O94806-1]
DR   Ensembl; ENST00000379066; ENSP00000368356; ENSG00000115825. [O94806-1]
DR   GeneID; 23683; -.
DR   KEGG; hsa:23683; -.
DR   UCSC; uc002rqd.4; human. [O94806-1]
DR   CTD; 23683; -.
DR   DisGeNET; 23683; -.
DR   GeneCards; PRKD3; -.
DR   H-InvDB; HIX0030377; -.
DR   HGNC; HGNC:9408; PRKD3.
DR   HPA; HPA029529; -.
DR   MIM; 607077; gene.
DR   neXtProt; NX_O94806; -.
DR   OpenTargets; ENSG00000115825; -.
DR   PharmGKB; PA33772; -.
DR   eggNOG; KOG4236; Eukaryota.
DR   eggNOG; ENOG410XQZ3; LUCA.
DR   GeneTree; ENSGT00840000129794; -.
DR   HOGENOM; HOG000015135; -.
DR   HOVERGEN; HBG003564; -.
DR   InParanoid; O94806; -.
DR   KO; K06070; -.
DR   OMA; YTSRDTL; -.
DR   OrthoDB; EOG091G02RG; -.
DR   PhylomeDB; O94806; -.
DR   TreeFam; TF314320; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; O94806; -.
DR   SIGNOR; O94806; -.
DR   ChiTaRS; PRKD3; human.
DR   EvolutionaryTrace; O94806; -.
DR   GeneWiki; PRKD3; -.
DR   GenomeRNAi; 23683; -.
DR   PRO; PR:O94806; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115825; -.
DR   CleanEx; HS_PRKD3; -.
DR   ExpressionAtlas; O94806; baseline and differential.
DR   Genevisible; O94806; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:CACAO.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0089700; P:protein kinase D signaling; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22968; PTHR22968; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000552; PKC_mu_nu_D2; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Serine/threonine-protein kinase; Transferase; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    890       Serine/threonine-protein kinase D3.
FT                                /FTId=PRO_0000055717.
FT   DOMAIN      416    532       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      576    832       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     154    204       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     271    321       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     582    590       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    699    699       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     605    605       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       6      6       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES      37     37       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES      41     41       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     213    213       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     216    216       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     364    364       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     535    535       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     539    539       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8K1Y2}.
FT   MOD_RES     731    731       Phosphoserine; by PKC.
FT                                {ECO:0000250|UniProtKB:Q15139}.
FT   MOD_RES     735    735       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:Q15139}.
FT   VAR_SEQ     595    611       HRKTGRDVAIKVIDKMR -> QLQPFAYCTHYFKNWKM
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_029405.
FT   VAR_SEQ     612    890       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_029406.
FT   VARIANT      42     42       N -> D (in dbSNP:rs11896614).
FT                                /FTId=VAR_037147.
FT   VARIANT     128    128       A -> T (in dbSNP:rs17852819).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037148.
FT   VARIANT     225    225       P -> S (in dbSNP:rs34280934).
FT                                /FTId=VAR_050561.
FT   VARIANT     445    445       L -> I (in dbSNP:rs55912911).
FT                                /FTId=VAR_061532.
FT   VARIANT     546    546       Q -> R (in dbSNP:rs17856887).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037149.
FT   VARIANT     716    716       V -> M (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042336.
FT   MUTAGEN     156    156       T->A: Slight loss in ability to bind DAG
FT                                and phorbol-ester; when associated with
FT                                F-158. {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     158    158       Y->F: Slight loss in ability to bind DAG
FT                                and phorbol-ester; when associated with
FT                                A-156. {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     165    165       P->G: No effect on ability to bind
FT                                phorbol ester, loss of ability to bind
FT                                DAG, reduced DAG-induced membrane
FT                                translocation.
FT                                {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     166    166       T->A: Slight loss in ability to bind DAG
FT                                and phorbol-ester.
FT                                {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     170    170       Y->F: Slight loss in ability to bind DAG
FT                                and phorbol-ester.
FT                                {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     282    282       P->G: No effect on ability to bind
FT                                phorbol ester, increase in ability to
FT                                bind DAG. {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     284    284       I->V: Slight increase in ability to bind
FT                                DAG, no effect on phorbol-ester binding.
FT   MUTAGEN     293    293       K->W: Increased ability to bind DAG, no
FT                                effect on phorbol-ester binding.
FT                                {ECO:0000269|PubMed:18076381}.
FT   STRAND      417    429       {ECO:0000244|PDB:2D9Z}.
FT   STRAND      434    443       {ECO:0000244|PDB:2D9Z}.
FT   STRAND      445    449       {ECO:0000244|PDB:2D9Z}.
FT   TURN        462    464       {ECO:0000244|PDB:2D9Z}.
FT   STRAND      477    479       {ECO:0000244|PDB:2D9Z}.
FT   STRAND      485    489       {ECO:0000244|PDB:2D9Z}.
FT   STRAND      494    497       {ECO:0000244|PDB:2D9Z}.
FT   TURN        508    514       {ECO:0000244|PDB:2D9Z}.
FT   HELIX       517    532       {ECO:0000244|PDB:2D9Z}.
SQ   SEQUENCE   890 AA;  100471 MW;  66D5E7E7235064F5 CRC64;
     MSANNSPPSA QKSVLPTAIP AVLPAASPCS SPKTGLSARL SNGSFSAPSL TNSRGSVHTV
     SFLLQIGLTR ESVTIEAQEL SLSAVKDLVC SIVYQKFPEC GFFGMYDKIL LFRHDMNSEN
     ILQLITSADE IHEGDLVEVV LSALATVEDF QIRPHTLYVH SYKAPTFCDY CGEMLWGLVR
     QGLKCEGCGL NYHKRCAFKI PNNCSGVRKR RLSNVSLPGP GLSVPRPLQP EYVALPSEES
     HVHQEPSKRI PSWSGRPIWM EKMVMCRVKV PHTFAVHSYT RPTICQYCKR LLKGLFRQGM
     QCKDCKFNCH KRCASKVPRD CLGEVTFNGE PSSLGTDTDI PMDIDNNDIN SDSSRGLDDT
     EEPSPPEDKM FFLDPSDLDV ERDEEAVKTI SPSTSNNIPL MRVVQSIKHT KRKSSTMVKE
     GWMVHYTSRD NLRKRHYWRL DSKCLTLFQN ESGSKYYKEI PLSEILRISS PRDFTNISQG
     SNPHCFEIIT DTMVYFVGEN NGDSSHNPVL AATGVGLDVA QSWEKAIRQA LMPVTPQASV
     CTSPGQGKDH KDLSTSISVS NCQIQENVDI STVYQIFADE VLGSGQFGIV YGGKHRKTGR
     DVAIKVIDKM RFPTKQESQL RNEVAILQNL HHPGIVNLEC MFETPERVFV VMEKLHGDML
     EMILSSEKSR LPERITKFMV TQILVALRNL HFKNIVHCDL KPENVLLASA EPFPQVKLCD
     FGFARIIGEK SFRRSVVGTP AYLAPEVLRS KGYNRSLDMW SVGVIIYVSL SGTFPFNEDE
     DINDQIQNAA FMYPPNPWRE ISGEAIDLIN NLLQVKMRKR YSVDKSLSHP WLQDYQTWLD
     LREFETRIGE RYITHESDDA RWEIHAYTHN LVYPKHFIMA PNPDDMEEDP
//
